iBET’s Advanced Bioanalytics R&D Presented at Gene and Cell Therapies 2025 in Munich

iBET Latest Research on AAV and HCP Characterization

iBET scientist Sofia Carvalho participated in the 4th Gene and Cell Therapies conference- CMC, CGT & Vector Manufacturing Summit, held June 04-05, in Munich, Germany.

The Gene and Cell Therapies conference is dedicated to accelerating progress in CMC and quality development of gene and cell therapy (GCT) products.

Sofia Carvalho delivered an oral communication on” Unveiling AAV Quality Attributes and HCP Profiling using Advanced Bioanalytics for Bioprocess Characterization”. This study included:

  • Viral proteins (VP) identity analysis by Mass Spectrometry (MS) and Capillary Electrophoresis methods;
  • AAV capsid Post Translational Modifications assessment using an MS based multi-attribute method (MAM) workflow;
  • Host Cell Protein (HCP) profiling using MS;
  • Study of how bioprocess parameters affect HCP levels and capsid Critical Quality Attributes.

Congratulations to Sofia for once again sharing iBET’s advancements on bioanalytics with the scientific international community.

Related news

iBET’s Research at ECI Advancing Manufacture of Cell & Gene Therapies IX Conference: Best Poster Award
February 12, 2026

iBET at PEGS Europe 2025: Advancing Biopharmaceuticals’ Development
November 18, 2025

CTOO Pedro Cruz Participates in Festival of Biologics 2025
October 9, 2025

iBET’s gene therapy research awarded at ESACT Frontiers Retreat 2025
July 16, 2025

iBET at Genetics Conference SPG2025 with Best Oral Presentation Award
June 27, 2025